Ioannides CG - Search Results

1

Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex.

Babcock B, Anderson BW, Papayannopoulos I, Castilleja A, Murray JL, Stifani S, Kudelka AP, Wharton JT, Ioannides CG. Babcock B, et al. Among authors: ioannides cg. Mol Immunol. 1998 Dec;35(17):1121-33. doi: 10.1016/s0161-5890(98)00100-x. Mol Immunol. 1998. PMID: 10395201

2

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

Fisk B, Blevins TL, Wharton JT, Ioannides CG. Fisk B, et al. Among authors: ioannides cg. J Exp Med. 1995 Jun 1;181(6):2109-17. doi: 10.1084/jem.181.6.2109. J Exp Med. 1995. PMID: 7539040 Free PMC article.

3

Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.

Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Ioannides CG, et al. J Immunol. 1993 Oct 1;151(7):3693-703. J Immunol. 1993. PMID: 7690810

4

Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.

Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA. Ioannides CG, et al. Cell Immunol. 1993 Oct 1;151(1):225-34. doi: 10.1006/cimm.1993.1233. Cell Immunol. 1993. PMID: 7691418

5

Characterization of T-cell receptor V beta repertoire in ovarian tumour-reacting CD3+ CD8+ CD4- CTL lines.

Fisk B, Flytzanis CN, Pollack MS, Wharton JT, Ioannides CG. Fisk B, et al. Among authors: ioannides cg. Scand J Immunol. 1994 Dec;40(6):591-600. doi: 10.1111/j.1365-3083.1994.tb03510.x. Scand J Immunol. 1994. PMID: 7848491

6

Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro.

Fisk B, Chesak B, Pollack MS, Wharton JT, Ioannides CG. Fisk B, et al. Among authors: ioannides cg. Cell Immunol. 1994 Sep;157(2):415-27. doi: 10.1006/cimm.1994.1238. Cell Immunol. 1994. PMID: 7915203

7

Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes.

Fisk B, Anderson BW, Gravitt KR, O'Brian CA, Kudelka AP, Murray JL, Wharton JT, Ioannides CG. Fisk B, et al. Among authors: ioannides cg. Cancer Res. 1997 Jan 1;57(1):87-93. Cancer Res. 1997. PMID: 8988046

8

Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides.

Fisk B, Hudson JM, Kavanagh J, Wharton JT, Murray JL, Ioannides CG, Kudelka AP. Fisk B, et al. Among authors: ioannides cg. Anticancer Res. 1997 Jan-Feb;17(1A):45-53. Anticancer Res. 1997. PMID: 9066629

9

Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.

Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith TL, Grabstein KH, Wharton JT, Ioannides CG, Murray JL. Tuttle TM, et al. Among authors: ioannides cg. Clin Cancer Res. 1998 Aug;4(8):2015-24. Clin Cancer Res. 1998. PMID: 9717833

10

Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides.

Peoples GE, Anderson BW, Fisk B, Kudelka AP, Wharton JT, Ioannides CG. Peoples GE, et al. Among authors: ioannides cg. Ann Surg Oncol. 1998 Dec;5(8):743-50. doi: 10.1007/BF02303486. Ann Surg Oncol. 1998. PMID: 9869522

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Search Page

Filters